Clinical Chronic Rhinosinusitis Outcomes in Pediatric Patients with Cystic Fibrosis

Frank W. Virgin, MD

Objectives: Chronic rhinosinusitis and nasal polyposis are common conditions in cystic fibrosis (CF). Approximately 2–3% of pediatric CF patients per year have sinus disease requiring surgery. It has been well established that there is a significant negative impact on quality of life associated with chronic rhinosinusitis (CRS) in the non-CF patient population. However, the impact of CRS on the pediatric CF population remains uncertain. The purpose of this article is to review the current state of outcome measures for CRS in pediatric CF patients.

Data Sources: PubMed and EMBASE literature review

Methods: PubMed and EMBASE electronic databases were searched using Boolean searches that incorporated mesh headings and plain language for quality of life, symptom evaluation, pediatric patients, and sinusitis/rhinosinusitis. Studies were included if the study primarily evaluated a pediatric Cystic Fibrosis-Chronic Rhinosinusitis (CF-CRS) population and the primary outcome measure was quality of life evaluation.

Results: The search yielded 34 unique articles. A total of 7 articles met inclusion criteria

Conclusions: Despite the high frequency of chronic rhinosinusitis in the pediatric CF patient population, its impact on quality of life is not well understood. Currently there is a lack of a validated disease specific quality of life instruments available to assess the impact of CRS on the pediatric CF patient population.

Key Words: Chronic sinusitis, cystic fibrosis, patient reported outcomes, quality of life.

Level of Evidence: 5.

INTRODUCTION

Individuals with cystic fibrosis (CF) have an incidence of chronic rhinosinusitis (CRS) approaching 100%, which is often associated with nasal polyposis (6–48%). However, data from the US Cystic Fibrosis Foundation (CFF) registry indicates that only 2–3% of pediatric patients per year have sinus disease requiring surgery. Other single-center studies have documented that approximately 10–20% of CF patients require surgical management of their sinus disease. Despite the high prevalence of CRS in the CF population, little is known about the optimal treatment, indications for surgery, and outcomes of treatment for CF CRS, leading to wide variation in practice patterns. A recent study demonstrated that there is large variation in the frequency of sinus surgery (1–24%) in 29 of the largest US pediatric hospitals. The reason for this variation is uncertain.

Health related quality of life outcome measures have become an increasingly important part of health care delivery and our evaluation of the care that is delivered by our system. Increasingly, clinical trials require patient-reported outcome measures (PROs) to be part of primary or secondary endpoints. However, the instruments used for these purposes vary greatly and there is no “gold standard” for how these outcomes are measured or reported. The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is the most widely used PRO for cystic fibrosis. This is a disease-specific health-related quality-of-life instrument (HRQOL) based on the 2 weeks prior to the patient encounter. There are 4 versions of the CFQ-R that include the ages 3–6, 6–13, and 14 through adulthood. Interviewer format is utilized until the age of 12. The questionnaire measures several domains including physical functioning, vitality, health perceptions, respiratory symptoms, treatment burden, role functioning, emotional functioning, and social functioning. There are no specific domains in this instrument evaluating sinusitis.

Currently, numerous health related quality of life instruments evaluating overall health in the general population exist. The SF-36 and SF-12 both measure physical and mental health, and the SF-10 health survey for children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire (CHQ). The SF-10 provides coverage across a wide range of domains, and is scored to produce physical and psychosocial health summary measures. The Health Utilities Index-3 (HUI-3), a comprehensive multi-attribute (generic) health status classification system, has previously been validated in the pediatric population.
| Author          | Type                      | Study Purpose                                | Patients (n) | Ages | Pre- and Post-operative comparison | QOL measure | Duration of benefit measured | Results                                                                 |
|-----------------|---------------------------|----------------------------------------------|--------------|------|------------------------------------|-------------|-------------------------------|-------------------------------------------------------------------------|
| Jones et al.    | Retrospective review and phone call survey | Evaluate pre- and post-surgical symptom scores | 17           | 3–30 | Yes                                | Non-validated symptom questionnaire | No              | Conclusion: that there was postoperative improvement in symptoms. No statistical analysis |
| Friedman et al. | Prospective data collection | Compare QOL scores with pulmonary function   | 51           | 7–20 | No                                 | SNOT-16     | No                            | SNOT-16 score was predictive of FEV1 in patients <12 years of age       |
| Keck et al.     | Prospective data collection | Compare pre- and post-surgical symptom scores | 26           | 3–33 | Yes                                | Non-validated symptom score      | No              | Improved symptoms following treatment                                   |
| Taylor et al.   | Prospective cohort study   | Compare pre- and post-surgical symptom scores | 10 CF patients 11 non-CF | 5–18 | Yes                                | PedsQLTM SNOT-16 SN-5            | No              | Preoperative impairment; improvement with sinus surgery                  |
| Thamboo et al.  | Cross sectional study      | SNOT-22 to predict presence of polyps        | 37           | 6–18 | No                                 | SNOT-22 UPSIT                      | No              | SNOT-22 score may assist in predicting presence of polyps               |
| Wentzel et al.  | Prospective data collection | Comparison of SN-5 score with frequency of sinusitis exacerbation or antibiotic use, missed days of school, and missed activities | 50           | 2–12 | No                                 | SN-5                                   | No              | Worse SN-5 scores were associated with more frequent sinusitis exacerbations, antibiotic use, missed days of school, and missed activities |
| Chan et al.     | Prospective data collection | Comparison of CRS diagnosis with SN-5 scores | 47           | 2–20 | NO                                 | SN-5                                   | No              | High prevalence of CRS with low impact on QOL                           |

QOL = quality of life; SNOT = sinonasal outcomes test; CRS = chronic rhinosinusitis; SN-5 = sinonasal-5; UPSIT = university of pennsylvania smell identification test; CF = cystic fibrosis; PedsQLTM = pediatric quality of life inventory.
populations for numerous disease states and is both reliable and generalizable in pediatric patients with acute illness. The HUI-3, for instance, assesses domains including vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain. However, generic HRQOL instruments suffer from an important shortcoming, namely that they are designed to be applicable to a wide variety of populations with many different underlying conditions. As a result, they may not be sufficiently sensitive for capturing meaningful differences among patients with a specific condition or chronic symptoms.

Within the otolaryngology subspecialty, several HRQOL instruments have been validated and are used regularly to evaluate patients with CRS (Table I). The Sinonasal Outcome Test (SNOT-22) is a HRQOL instrument that has been previously validated. This instrument was developed to assess patient-reported outcomes in the chronic rhinosinusitis (CRS) adult patient populations. The SNOT-22 evaluates HRQOL in such areas as physical problems, functional limitations and emotional consequences. Scoring of each question centered on a problem ranks on a 5-point scale (0 = no problem to 5 = problem is as bad as it can get) and is evaluated based on the problems from the previous 2-week period.

While several studies have been conducted to assess the reliability and generalizability of HRQOL instruments developed for adult otolaryngology patients, very few instruments appropriately evaluate the pediatric population. One scale, The Sinonasal-5 (SN-5) survey, has been used to evaluate the severity of sinonasal disease in patients between the ages of 2 and 12. This survey is comprised of 5 domains including sinus infection, nasal obstruction, allergy symptoms, emotional distress, and activity limitations. Within each domain are symptom clusters that are scored on a 7-point scale (1 = none of the time to 7 = all of the time). Additionally, the survey asks parents to rate the overall quality of life of their child on a scale from 0 to 10, with 0 representing “worse possible quality of life” and “10 representing the best quality of life.”

CRS has been clearly demonstrated to have a negative impact on the quality of life in the non-CF patient population. In fact the impact has been shown, in adult patients, to rival that of congestive heart failure and chronic kidney disease. In pediatric patients with CRS it has been demonstrated that CRS also has a significant negative impact on health related quality of life. However, the impact of CRS on the pediatric CF population is not as well defined.

The purpose of this paper is to review current outcome measures for CRS in pediatric CF patients and to highlight the gaps in these measures that currently exist.

**METHODS**

PubMed and EMBASE electronic databases were searched using Boolean searches that incorporated mesh headings and plain language for quality of life, symptom evaluation, pediatric patients, and sinusitis/rhinosinusitis. A single author reviewed the results of these searches to determine applicability to the review topic. Pediatric was defined as patients ≤18. Studies were included if the study primarily evaluated a pediatric CF-CRS population and the primary outcome measure was quality of life evaluation.

**RESULTS**

The PubMed and EMBASE search generated a total of 34 unique articles. A total of 7 articles met criteria for inclusion. (Table II) The articles not included in this review were studies of adult patients, non-cystic fibrosis...
patients, did not have quality of life as a primary outcome measure, or were non-chronic rhinosinusitis related.

Jones et al. in 1993 attempted to evaluate the correlation between sinus surgery and symptoms in a group of pediatric patients with cystic fibrosis. In this study, 16 pediatric patients and 1 adult patient were contacted by phone 5–70 months following endoscopic sinus surgery. They were asked to report frequency of headaches per month pre- and post-intervention, as well as rate the symptoms of nasal obstruction, nasal discharge, post-nasal drip, halitosis, and cough. These symptoms were rated and scored as occurring constantly (4 points), often (3 points), seldom (2 points), and never (1 point). The study reported that there was a decrease in the symptom domains nasal obstruction, purulent nasal discharge, and postnasal drip. However, no statistical analysis of the pre- and postoperative scores was performed. The conclusion of the paper, based on the findings, was that endoscopic sinus surgery improved quality of life in the study patient population.

The relationship between sinus disease and reactive airway disease has been well established. This relationship in cystic fibrosis is not as well defined. Friedmann and Stewart in 2006 evaluated the link between sinus quality of life and pulmonary function. In this study the Sinonasal Outcomes Test-16 (SNOT-16) was used to evaluate symptoms in a CF population aged 7–20 years (mean 11.7). SNOT-16 is an instrument developed by Piccirillo et al. and subsequently validated in an adult population by Anderson et al. This instrument evaluates symptoms and the social and emotional consequences of the patient’s rhinosinusitis. A higher score indicates worse impact on quality of life and functional status. Using univariate correlation and multivariable regression they attempted to demonstrate a link between SNOT-16 scores and forced expiratory volume in one second (FEV1). When the population was taken as a whole there was no correlation. However, when dividing the patient population into ages <12 and ≥12 they found that SNOT-16 score was predictive of FEV1 in children <12 (p = .012). In younger children a worse SNOT-16 score was associated with lower FEV1. The authors concluded, based on the results of this study, that the SNOT-16 could be used to assess sinus interventions on pulmonary status.

In 2007 Keck et al. evaluated a group of 26 cystic fibrosis patients with CRS. The average age was 3–33. Pre and postoperative symptom scores were evaluated using a non-validated 6-point Likert scale. There were statistically significant improvements pre and post operatively for the domains: facial pain (p = .003), headache (p = .001), nasal obstruction (p ≤ .001), post nasal drip (p ≤ .001), anterior rhinorrhea (p = .002), and total rhinosinusitis symptom score (p ≤ .001). The conclusion of this paper was that endoscopic sinus surgery provided significant relief from nasal and facial symptoms associated with CRS.

Taylor et al. in 2014 evaluated both CF and non-CF CRS. In this study, 10 CF patients and 11 non-CF patients were included. Each parent completed Pediatric Quality of Life Inventory TM (PedsQLTM), SNOT-16 at 2 weeks prior to surgery and at 1–3 months post-operatively. The Peds QLTM measures the core dimensions of health as defined by the Word Health Organization and school functioning in patients 2–18. The age range of the study population was 5–18. When pre- and post-operative scores were compared for the CF population, SN-5 parent reported scores dropped by 1.85 (p = .0001). SNOT-16 parent scores declined by 10.4 (p = .02) and SNOT-16 child reported scores declined by 6.4 (p = .08). There was no significant decrease in child or parent reported PedsQLTM scores. The conclusion of this study was that there is improvement following sinus surgery in CF patients with CRS.

Thamboo et al. in 2014 utilized the SNOT-22 and University of Pennsylvania Smell Identification Test (UPSIT) in an attempt to predict the presence of nasal polyposis in a group of CF patients age 6–18. Their study did not specifically evaluate the impact of disease on the SNOT-22 scores, but suggested it may be used as a tool to predict the presence of nasal polyposis in the pediatric CF population. The study found that SNOT-22 score greater than 11 had a sensitivity of 75% and specificity of 59% in the detection of nasal polyposis.

More recently, Wentzel et al. evaluated a group of 50 consecutive CF patients age 2–12 that presented to a rhinology practice. The quality-of-life visual analog scale was strongly negatively correlated with reported SN-5 scores (r = −0.55, p = .0006). Additionally, worse sinus-specific QOL as measured by the SN-5 score was associated with an increase in diagnosis of sinusitis, prescription of antibiotics, and missed days of school or recreational activities due to sinusitis symptoms. No correlation was found between SN-5 score and pulmonary function or recent hospitalization. Their conclusion was that the SN-5 was a quick and qualitative method for monitoring CRS in this patient population.

Finally, in a study published in 2016, Chan et al. evaluated a group of pediatric CF patients with an age range of 2–20 (average 12.9). One hundred two consecutive patients were given a screening questionnaire for diagnosis of CRS and the SN-5 during a routine clinic visit. Of the 102 participants, 47 completed the surveys. Depending on the diagnostic criteria used 11–38% of the patient population had CRS. Mean domain (2.16; 95% CI, 2.02–2.30) and overall visual-analog scale (8.26; 95% CI, 8.01–8.51) scores on the SN-5 were consistent with minimal effect on QOL. It was concluded that there is a high prevalence of symptomatic CRS in this patient population, but that it had a low impact on quality of life.

DISCUSSION

Health-related QOL outcomes have become increasingly important. Patients with cystic fibrosis have a high incidence of chronic rhinosinusitis, but the impact of this disease process, on these patients’ quality of life, is not well understood. Several papers have attempted to evaluate this. The SN-5 is a questionnaire that has been validated in the non-CF patient population ages 2–12. By design, it is to be completed by the patients’ proxy/primary caregiver. Several of the studies in this review use the SN-5
as part of their study design, however, only the study by Wentzel et al. used it exclusively for the 2–12 population. In the studies by Taylor and Thamboo the SNOT-16 and SNOT-22 were used as part of the study design. However, these instruments are only validated in the >18 age group and their utility in the pediatric patient population is not well understood. Additionally, although used in multiple adult CF patient studies, the SNOT-22 has not been validated in the CF population.

Several studies in the adult population have used the SNOT-22 in the CF population and have determined it to be a valuable tool. Habib et al. demonstrated that a score >21 was predictive of CRS diagnosis in a group of adult CF patients. Other studies have evaluated the use of SNOT-22 for pre and postoperative symptom evaluation and have determined it to be a useful tool to follow patients over time.

This review highlights the fact that there is a paucity of literature evaluating the quality of life affects on pediatric patients with CF associated CRS. However, the use of these instruments in the adult CF population has shown promise. Currently, no disease specific quality of life measure exists for this patient population. Although the SN-5 has shown promise, it is only validated in the non-CF 2–12 year-old patient population. This leaves no validated measurement tool for the >12 to <18 population. It is likely that the true impact of CRS on pediatric CF patients will not be known until a validated measure exists that encompasses all patients <18.

**CONCLUSION**

Despite the high frequency of chronic rhinosinusitis in the pediatric CF patient population, its impact on quality of life is not well understood. Currently there is a lack of a validated disease specific, quality of life instrument, available to assess the impact of CRS on the pediatric CF patient population.

**BIBLIOGRAPHY**

1. Brihaye P, Clement PA, Dab I, Desprechin B. Pathological changes of the lateral nasal wall in patients with cystic fibrosis (mucoviscidosis). *Int J Ped Otorhinolaryngol* 1994;28:141–147.
2. Cepero R, Smith RJ, Catlin FI, Bressler KL, Furuta GT, Shandera KC. Cystic fibrosis—an otolaryngologic perspective. *Otolaryngol Head Neck Surg* 1987;97:356–360.
3. Gentile VG, Isaacson G. Patterns of sinusitis in cystic fibrosis. *Laryngoscope* 1996;106:1005–1009.
4. Roshe KW, Jones DT, Rahbar R, Lahiri T, Auerbach AD. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery? *Int J Pediatr Otorhinolaryngol* 2001;61:113–119.
5. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2013 Annual Data Report. Bethesda, MD. 2013.
6. Ramsey B, Richardson MA. Impact of sinusitis in cystic fibrosis. *J Allergy Clin Immunol* 1992;90:547–552.
7. Virgin FW, Huang L, Roberson DW, Sawicki GS. Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. *Pediatr Pulmonol* 2014.
8. Wentzel JL, Virella-Lowell I, Schlesser RJ, Soler ZM. Quantitative sinonasal symptom assessment in an unselected pediatric population with cystic fibrosis. *Am J Rhinol Allergy* 2015;29:357–361.
9. Retsch-Bogart GZ, Quittner AL, Gibbons RL et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. *Chest* 2009;135:1223–1232.
10. Quittner AL, Bus A, Messer MA, Modic AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. *Chest* 2005;128:2347–2354.
11. Quittner AL, Sawicki GS, McMullen A et al. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. *Qual Life Res* 2012;21:1279–1290.
12. Quittner AL, Sawicki GS, McMullen A et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. *Qual Life Res* 2012;21:1267–1278.
13. Amor R, Subbarao P, Janjua A et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. *Thorax* 2010;65:379–383.
14. Buzizer JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ* 1992;305:160–164.
15. Gandel E, Ware JE, Aaronson NK et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. *Int Q. Life Assessment*. J Clin Epidemiol 1998;51:1171–1178.
16. Turner-Bowker DB, Kosinski M, Zhao J, Saris-Baglama R. SF-10 for Children: A User’s Guide. Lincoln, RI: QualityMetric Incorporated, 2003.
17. Cunningham MJ, Chiu EJ, Landgraf JM, Gliklich RE. The health impact of chronic recurrent rhinosinusitis in children. *Arch Otolaryngol Head Neck Surg* 2000;126:1363–1368.
18. Ladhner TR, Westrick AC, Wellons JC, 3rd, Shannon CN. Health-related quality of life in pediatric Chiari Type I malformation: the Chiari Health Index for Pediatrics. *J Neurosurg Pediatr* 2016;17:76–85.
19. Feeny D, Furlong W, Torrance GW et al. Multivariate and single-attribute utility functions for the health utilities index mark 3 system. *Med Care* 2002;40:113–128.
20. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. *Clin Otolaryngol* 2009;34:447–454.
21. Kay DJ, Rosenfeld RM. Quality of life for children with persistent sinusonal symptoms. *Otolaryngol Head Neck Surg* 2003;128:17–26.
22. Soler ZM, Wittenberg E, Schlesser RJ, MacE JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. *Laryngoscope* 2011;121:2672–2678.
23. Jones JW, Parsons DS, Cuyler JP. The results of functional endoscopic sinus (FES) surgery on the symptoms of patients with cystic fibrosis. *Int J Pediatr Otorhinolaryngol* 1993;28:25–32.
24. Rachelefsky GS, Katz RM, Siegel SC. Chronic sinus disease with associated reactive airway disease in children. *Pediatrics* 1984;73:526–529.
25. Friedman EM, Stewart M. An assessment of sinus quality of life and pulmonary function in children with cystic fibrosis. *Am J Rhinol* 2006;20:568–572.
26. Anderson ER, Murphy MP, Weymuller EA Jr. Clinimetric evaluation of the Sinonasal Outcome Test-16. *Student Research Award 1998*.
27. Keck T, Rozsaai A. Medium-term symptom outcomes after paranasal sinus surgery in children and young adults with cystic fibrosis. *Laryngoscope* 2007;117:475–479.
28. Varni JW, Seid M, Rode CA. The PedsQL: measurement tool for the pediatric quality of life inventory. *Med Care* 1999;37:126–139.
29. Taylor RJ, Miller JD, Ross AB et al. Comprehensive quality of life outcomes for pediatric patients undergoing endoscopic sinus surgery. *Rhinology* 2014;52:327–333.
30. Thamboo A, Santos RC, Naidoo I, Rahmanian R, Chilvers MA, Chadka NR. Use of the SNOT-22 and UPSIT to appropriately select pediatric patients with cystic fibrosis who should be referred to an otolaryngologist: cross-sectional study. *JAMA Otolaryngol Head Neck Surg* 2014;140:934–939.
31. Chan DK, McNamara S, Park JS, Vajda J, Gibson RL, Parikh SR. Sinonasal Quality of Life in Children With Cystic Fibrosis. *JAMA Otolaryngol Head Neck Surg* 2016;142:743–749.
32. Virgin FW, Rowe SM, Wade MB et al. Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis. *Am J Rhinol Allergy* 2012;26:70–75.
33. Habib AR, Quin BS, Buxton JA et al. The Sino-Nasal Outcome Test-22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis. *Int Forum Allergy Rhinol* 2015;5:1111–1117.
34. Savastano V, Bertin S, Vittori T, Tripodi C, Magliulo G. Evaluation of chronic rhinosinusitis management using the SNOT-22 in adult cystic fibrosis patients. *Eur Rev Med Pharmacol Sci* 2014;18:1985–1989.